Journal article
β-Amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia
P Bourgeat, G Chételat, VL Villemagne, J Fripp, P Raniga, K Pike, O Acosta, C Szoeke, S Ourselin, D Ames, KA Ellis, RN Martins, CL Masters, CC Rowe, O Salvado
Neurology | Published : 2010
Abstract
Objective: To investigate whether global and regional β-amyloid (Aβ) burden as measured with C Pittsburgh compound B (PIB) PET is associated with hippocampal atrophy characterized using MRI in healthy controls and patients with amnestic mild cognitive impairment (aMCI) or Alzheimer disease (AD). METHODS: Ninety-two elderly healthy controls, 32 subjects with aMCI, and 35 patients with AD were imaged using C-PIB PET and MRI. Hippocampal volume was measured and PIB standardized uptake value ratio was extracted after partial volume correction within 41 regions of interest. Global, regional, and voxel-based correlations between PIB and hippocampal volume were computed for each group. RESULTS: In ..
View full abstractGrants
Funding Acknowledgements
[ "The Australian Imaging, Biomarkers and Lifestyle Research Group receives funding from the Commonwealth Scientific and Industrial Research Organisation. Dr. Szoekes' research has been supported by the Alzheimer's Association of Australia and the National Health and Medical Research Council.", "Dr. Bourgeat and Dr. Chetelat report no disclosures. Dr. Villemagne serves as a consultant to Bayer Schering Pharma. Dr. Fripp, Dr. Raniga, Dr. Pike, and Dr. Acosta report no disclosures. Dr. Szoeke may accrue revenue on a pending patent (filed: 2003): diagnostic assay for seizure prediction; and has received speaker honoraria from Pfizer Inc and Lundbeck Inc. Dr. Ourselin reports no disclosures. Dr. Ames has served/serves on scientific advisory boards for Novartis, Janssen, and Pfizer Inc; has received funding for travel from Janssen and Pfizer Inc; serves as Editorin-Chief of International Psychogeriatrics; receives royalties from publishing Dementia, 3rd ed. (Hodder Arnold, 2005); has received speaker honoraria from Pfizer and Lundbeck; and receives research support from Eli Lilly and Company, GlaxoSmithKline, Novartis, and Forest Laboratories, Inc. Dr. Ellis reports no disclosures. Dr. Martins serves as Senior Editor of the Journal of Alzheimer's Disease; and serves as a consultant to and holds stock in Alzhyme. Dr. Masters, Dr. Rowe, and Dr. Salvado report no disclosures." ]